Aligos Therapeutics, Inc. Cash Flow Statement
ALGS|6 years of annual SEC 10-K data (FY2020-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 6 fiscal years. All figures from audited SEC 10-K filings.
Aligos Therapeutics, Inc. used $83M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income | -$24.2M | -$131.2M | -$96.0M | -$128.3M | -$108.5M | -$52.3M |
| Depreciation & Amortization | - | - | $2.3M | $3.0M | $2.7M | $1.4M |
| Operating Cash Flow | -$82.5M | -$80.7M | -$79.4M | -$115.7M | -$74.3M | -$46.8M |
| Capital Expenditures | - | $130.0K | $943.0K | $892.0K | $2.1M | $2.8M |
| Free Cash Flow | - | -$80.9M | -$80.3M | -$116.6M | -$76.3M | -$49.6M |
| FCF Margin | - | -2239.6% | -1297.6% | - | - | - |